Cargando…

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease

BACKGROUND: The objective of this study was to determine whether neurotoxic kynurenine metabolites, induced by inflammation, in plasma and cerebrospinal fluid (CSF) are associated with symptom severity and nigral pathology in Parkinson's disease (PD). METHODS: Clinical and MRI data were obtaine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heilman, Patrick L., Wang, Ernest W., Lewis, Mechelle M., Krzyzanowski, Stanislaw, Capan, Colt D., Burmeister, Amanda R., Du, Guangwei, Escobar Galvis, Martha L., Brundin, Patrik, Huang, Xuemei, Brundin, Lena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754343/ https://www.ncbi.nlm.nih.gov/pubmed/32710594 http://dx.doi.org/10.1002/mds.28202

Ejemplares similares

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease
por: Jellen, Leslie C., et al.
Publicado: (2021)

Cytokines and tryptophan metabolites can predict depressive symptoms in pregnancy
por: Sha, Qiong, et al.
Publicado: (2022)

Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
por: Thirtamara-Rajamani, Keerthi, et al.
Publicado: (2017)

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease
por: George, Sonia, et al.
Publicado: (2019)

Altered Tryptophan Catabolism in Placentas From Women With Pre-eclampsia
por: Keaton, Sarah A, et al.
Publicado: (2019)

Cytokine and Reward Circuitry Relationships in Treatment-Resistant Depression
por: Rengasamy, Manivel, et al.
Publicado: (2021)

Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene
por: Labandeira‐Garcia, Jose L., et al.
Publicado: (2022)

Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology
por: Coetzee, Simon G., et al.
Publicado: (2016)

T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils
por: George, Sonia, et al.
Publicado: (2021)

Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms
por: Xie, Aoji, et al.
Publicado: (2022)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

Parkinson’s Disease: We Care!
por: Bloem, Bastiaan R., et al.
Publicado: (2020)

Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls
por: Bacelis, Jonas, et al.
Publicado: (2021)

A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid
por: Schwieler, Lilly, et al.
Publicado: (2020)

The Times They Are a-Changin’: Parkinson’s Disease 20 Years from Now
por: Brundin, Patrik, et al.
Publicado: (2018)

Introduction
por: Patrik, Brundin
Publicado: (2017)

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
por: Sardi, S. Pablo, et al.
Publicado: (2018)

Is COVID-19 a Perfect Storm for Parkinson’s Disease?
por: Brundin, Patrik, et al.
Publicado: (2020)

Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2022)

Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis
por: Widner, Håkan, et al.
Publicado: (1988)

What’s to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?
por: Dunning, Christopher J.R., et al.
Publicado: (2013)

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
por: von Linstow, Christian U., et al.
Publicado: (2020)

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
por: Stott, Simon R. W., et al.
Publicado: (2021)

Height and nigral neuron density in Parkinson’s disease
por: Saari, Laura, et al.
Publicado: (2022)

Neuromelanin‐MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template‐Based Standardized Analysis
por: Xing, Yue, et al.
Publicado: (2022)

Linking α-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson’s disease
por: Kulkarni, Aishwarya S, et al.
Publicado: (2022)

Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy
por: Chatterjee, Diptaman, et al.
Publicado: (2019)

The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
por: Rey, Nolwen L., et al.
Publicado: (2016)

Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models
por: Burbulla, Lena F., et al.
Publicado: (2021)

Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala
por: Chen, Liqiang, et al.
Publicado: (2022)

Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinson’s Disease
por: Scholten, Marlieke, et al.
Publicado: (2017)

Reversing Parkinson Disease Model with in situ Converted Nigral Neurons
por: Qian, Hao, et al.
Publicado: (2020)

Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson’s disease
por: Pflug, Christina, et al.
Publicado: (2020)

Nigral volume loss in prodromal, early, and moderate Parkinson’s disease
por: Langley, Jason, et al.
Publicado: (2023)

Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines
por: Ventorp, Filip, et al.
Publicado: (2017)

Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?
por: Lema Tomé, Carla M., et al.
Publicado: (2012)

Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease
por: Li, Peipei, et al.
Publicado: (2021)

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?
por: Barker, Roger A., et al.
Publicado: (2016)

Parkinson Matters
por: Darweesh, Sirwan K.L., et al.
Publicado: (2018)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5tto4gn77bt941f5b7bao6fbi7